NuCana plc (NCNA)
NASDAQ: NCNA · Real-Time Price · USD
0.8900
+0.0172 (1.97%)
Apr 1, 2025, 4:00 PM EDT - Market closed
NuCana Employees
As of December 31, 2024, NuCana had 22 total employees, including 20 full-time and 2 part-time employees. The number of employees decreased by 6 or -21.43% compared to the previous year.
Employees
22
Change (1Y)
-6
Growth (1Y)
-21.43%
Revenue / Employee
n/a
Profits / Employee
-$1,081,037
Market Cap
5.04M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
NCNA News
- 12 days ago - NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 7 weeks ago - Aurion Biotech Appoints Donald Munoz as Chief Financial Officer - Business Wire
- 4 months ago - NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 5 months ago - NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel - GlobeNewsWire
- 6 months ago - Baillie Gifford's Strategic Acquisition of NuCana PLC Shares - GuruFocus
- 6 months ago - NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States - GlobeNewsWire
- 7 months ago - NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024 - GlobeNewsWire
- 7 months ago - NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study - GlobeNewsWire